Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

Jul 14, 2017
Source URL: https://qa1.novartis.us/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor-cosentyx-reinforcing-sustained-efficacy-and-safety-profile-psoriasis-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor-cosentyx-reinforcing-sustained-efficacy-and-safety-profile-psoriasis-0